Is NBIX or OKYO more undervalued in 2026?

CirclFi compares Neurocrine Biosciences, Inc. (NBIX) and OKYO Pharma Limited (OKYO) using 13 institutional-grade valuation models. NBIX has a Quality of Company score of 10.0/10 while OKYO scores 1.7/10.

Which is a better buy — NBIX or OKYO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NBIX and OKYO valuations compare?

NBIX at $158.30 and OKYO at $1.72 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NBIX vs OKYO Valuation Comparison 2026 — Intrinsic Value Analysis

NBIX

Biological Products, (No Diagnostic Substances)

Neurocrine Biosciences, Inc.

Quality

10.0

out of 10

Value Trap

SAFE

Price

$158.30

Last close

Models

13/13

Active

OKYO

Biological Products, (No Diagnostic Substances)

OKYO Pharma Limited

Quality

1.7

out of 10

Value Trap

—

Price

$1.72

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	NBIX Fair Value	NBIX Upside	OKYO Fair Value	OKYO Upside
Bayesian DCF	Intrinsic	$121.09	-23.5%	$0.43	-75.1%
Earnings Power Value	Intrinsic	$34.99	-77.9%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$155.07	-2.0%	$1.04	-39.6%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NBIX vs OKYO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NBIX vs OKYO — Which Stock Is More Undervalued?

NBIX scores higher with a 10.0/10 quality rating vs OKYO's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Neurocrine Biosciences, Inc. (NBIX) and OKYO Pharma Limited (OKYO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NBIX currently trades at $158.30 with a QOC of 10.0/10, while OKYO trades at $1.72 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).